We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Tarrytown, NY-based Regeneron Pharmaceuticals, Inc. (REGN - Free Report) is a biopharmaceutical company focused on the discovery, development and commercialization of products for the treatment of serious medical conditions including eye diseases, high LDL cholesterol. Currently, the company has three marketed products in its portfolio – Eylea, Arcalyst and Praluent.
Eye drug, Eylea, should continue to remain the key growth driver contributing significantly to the top line. Meanwhile, Regeneron received a major boost when its PCSK9 inhibitor, Praluent, which the company has co-developed with Sanofi, gained approval in the U.S. The cholesterol management market represents huge commercial potential.
In this scenario, investor focus should remain on the performance of Eylea and Praluent apart from the usual top-and bottom-line numbers.
Regeneron’s performance has been mixed so far. In the last four reported quarters, it has surpassed earnings estimates on three occasions and missed the same once .Overall, the company has recorded an average negative earnings surprise of 0.21%.
Regeneron Pharmaceuticals, Inc. Price and EPS Surprise
Currently, Regeneron has a Zacks Rank #4 (Sell), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Regeneron’s fourth-quarter 2016 earnings missed expectations. Our consensus called for EPS of $2.51 and the company reported EPS of $2.18 (including the impact of share-based compensation expenses and tax adjustments).
Revenues: Revenues in the reported quarter too fell short of expectations. Regeneron posted revenues of $1.23 billion, compared to our consensus estimate of $1.30 billion.
Key Stats: Eylea global net sales increased 17% year over year to $1.35 billion. Regeneron expects U.S. Eylea net sales to grow in single digits in 2017.
Pre-Market Trading: Shares were down around 1% in the pre-market trading.
Check back later for our full write up on this REGN earnings report later!
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest tickers for the entirety of 2017?
Who wouldn't? These 10 are painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. They are our primary picks to buy and hold. Be among the very first to see them >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Regeneron (REGN) Q4 Earnings Misses Estimates
Tarrytown, NY-based Regeneron Pharmaceuticals, Inc. (REGN - Free Report) is a biopharmaceutical company focused on the discovery, development and commercialization of products for the treatment of serious medical conditions including eye diseases, high LDL cholesterol. Currently, the company has three marketed products in its portfolio – Eylea, Arcalyst and Praluent.
Eye drug, Eylea, should continue to remain the key growth driver contributing significantly to the top line. Meanwhile, Regeneron received a major boost when its PCSK9 inhibitor, Praluent, which the company has co-developed with Sanofi, gained approval in the U.S. The cholesterol management market represents huge commercial potential.
In this scenario, investor focus should remain on the performance of Eylea and Praluent apart from the usual top-and bottom-line numbers.
Regeneron’s performance has been mixed so far. In the last four reported quarters, it has surpassed earnings estimates on three occasions and missed the same once .Overall, the company has recorded an average negative earnings surprise of 0.21%.
Regeneron Pharmaceuticals, Inc. Price and EPS Surprise
Regeneron Pharmaceuticals, Inc. Price and EPS Surprise | Regeneron Pharmaceuticals, Inc. Quote
Currently, Regeneron has a Zacks Rank #4 (Sell), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Regeneron’s fourth-quarter 2016 earnings missed expectations. Our consensus called for EPS of $2.51 and the company reported EPS of $2.18 (including the impact of share-based compensation expenses and tax adjustments).
Revenues: Revenues in the reported quarter too fell short of expectations. Regeneron posted revenues of $1.23 billion, compared to our consensus estimate of $1.30 billion.
Key Stats: Eylea global net sales increased 17% year over year to $1.35 billion. Regeneron expects U.S. Eylea net sales to grow in single digits in 2017.
Pre-Market Trading: Shares were down around 1% in the pre-market trading.
Check back later for our full write up on this REGN earnings report later!
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest tickers for the entirety of 2017?
Who wouldn't? These 10 are painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. They are our primary picks to buy and hold. Be among the very first to see them >>